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Introduction
There are two pharmacologic classes of drugs to consider for use when mydriasis (pupil dilation) of the eye is needed: alpha-adrenergic agonists and anticholinergics. 1 Alpha-adrenergic agonists act by stimulating contraction of the dilator muscle, which enlarges the pupil.
Anticholinergic agents cause dilation via relaxation of the iris sphincter muscle. Some anticholinergic agents also cause a cycloplegic effect, resulting in paralysis of the ciliary body in the eye. Most of these drugs are available commercially as single-ingredient products. 1 However, they are often used together as sequential drops, because no single drug has the ideal efficacy and safety profile for the wide range of patient parameters. [2] [3] [4] Mydriatic ophthalmic solutions are routinely used for comprehensive eye exams and surgical procedures. Traditionally, the protocol has consisted of administering the required single-ingredient eye drops one at a time, separated by 5-10 minutes each. This is burdensome for patients and the healthcare team alike, and may lead to an increase in medication error. A preferred method consists of using a combination solution with all of the required ingredients that can be administered to the patient all at once. However, there is limited selection for commercially available combination mydriatic solution products. 2 At the authors' healthcare facility, two combination mydriatic solutions are frequently prescribed for adult and pediatric patients, respectively. The adult formulation consists of phenylephrine 2.5% and tropicamide 1%, and the pediatric formulation consists of phenylephrine 2.5%, tropicamide 0.5%, and cyclopentolate 0.5%. Phenylephrine is an alpha-adrenergic agonist that causes dilation. 1, 5 Cyclopentolate and tropicamide are both anticholinergics, which cause dilation and also produce a cycloplegic effect. 1, 6, 7 These drugs also differ in their potency, onset and duration of action, and tolerability. Both the adult and pediatric formulations are prepared extemporaneously by the pharmacy department following the USP <797> requirements for sterile compounding. 8 Due to the high frequency of usage, it is desired to have a stock supply of both ophthalmic solutions available in the pharmacy inventory. However, in the absence of stability or sterility data, the default USP beyond-use date (BUD) of these two solutions stored at refrigeration is only three days. 8, 9 The purpose of this study is to generate the physical and chemical stability data of the two mydriatic ophthalmic solutions in order to extend their BUD to facilitate the pharmacy inventory management and timely dispensing for patient use.
Methods

Drug Source and Strength Labeling
The stability samples of this study were prepared using phenylephrine hydrochloride powder (USP grade) a , tropicamide ophthalmic solution USP 1% b , and cyclopentolate hydrochloride ophthalmic solution USP 1% c . Both tropicamide and cyclopentolate solutions were manufactured sterile products containing commonly used excipients for ophthalmic dosage forms, such as boric acid, edetate disodium, and 0.01% benzalkonium chloride (preservative).
The strengths of cyclopentolate and phenylephrine were expressed as the hydrochloride salt forms for all solutions used or prepared in this study. However, for simplicity, the hydrochloride salt designations are not restated in the remaining text.
Pediatric Formulation Preparation
Using proper aseptic technique in a vertical laminar airflow hood, 30 mL each of tropicamide 1% and cyclopentolate 1% solutions was obtained from the source bottles and mixed in a suitable container. Approximately 50% of this tropicamide/cyclopentolate mixture was added into a beaker pre-calibrated to 45-mL. An amount of 1.125 g phenylephrine powder was added to the beaker and stirred until fully dissolved. If necessary, the pH of the solution was adjusted to 4.2-5.8 using a small amount of 0.1 N HCl. Additional tropicamide/cyclopentolate mixture was added to the pre-calibrated beaker up to 45-mL for a final concentration of phenylephrine 2.5%, tropicamide 0.5%, and cyclopentolate 0.5%. The dilution due to the phenylephrine powder or pH adjustment was negligible as confirmed by the HPLC analysis of time zero samples (see Results and Discussion). The final solution was sterile-filtered and packaged into three sterile dropper bottles, approximately 15 mL each.
Adult Formulation Preparation
Using proper aseptic technique in a vertical laminar airflow hood, 45 mL of tropicamide 1% solution was obtained from source bottles and placed in a suitable container. Approximately half of the tropicamide solution was transferred to a beaker pre-calibrated to 45-mL. An amount of 1.125 g phenylephrine powder was added to the beaker and stirred until fully dissolved.
Additional tropicamide solution was added to the pre-calibrated beaker up to 45 mL for a final concentration of phenylephrine 2.5% and tropicamide 1.0%. The pH adjustment, sterilization, and packaging were conducted in the same manner as the pediatric formulation preparation. The final solution was sterile-filtered and packaged into three sterile dropper bottles, approximately 15 mL each.
Stability Study
Three 15-mL bottles each of the compounded pediatric and adult ophthalmic solutions were used throughout the stability study. All samples were stored in the refrigerator (2-8° C) and At each stability study time point, five standard solutions for each formulation were analyzed for calibration purpose. The standards were prepared from pure drug powders f,g,h and encompassed the 80% -120% range of the nominal drug concentrations in the diluted stability samples for HPLC analysis. Calibration curves were constructed via linear regression of the peak area versus the concentration for each drug. Each curve was found to be linear over the concentration range of the standards with r 2 > 0.995. All standard solutions were injected three times on each analysis day to assess the method precision. The intraday and interday coefficients of variation were found to be within 2.0%.
Forced Degradation Study
A short-term forced degradation study was performed to evaluate whether the HPLC method was stability indicating, thus capable of separating the potential degradation products from the parent drugs. Aqueous solutions of phenylephrine, tropicamide, and cyclopentolate at concentrations of 1.0, 0.2, and 0.2 mg/mL respectively were prepared from pure drug powders. f,g,h Samples of all three drug solutions were treated with 1N hydrochloric acid i (final pH ~2), 1N sodium hydroxide j (final pH ~12), and 30% hydrogen peroxide k (final concentration 3%). The samples treated with acid and base were incubated at 60° C. Those treated with hydrogen peroxide were incubated at 60° C or subjected to sunlight. All samples were assayed at time zero and subsequent time points ranging from 24 hours to 3 days until a minimum of 20% degradation had been reached in at least one sample for each drug. Significant degradation was observed in all three drug samples treated with hydrogen peroxide and in cyclopentolate sample at pH 12. All degradation products were separated from the three parent drugs by the gradient HPLC method, and no major interfering peaks were noted. Therefore, the HPLC method was considered as stability indicating and suitable for the stability study.
Results and Discussion
There is an unmet need for combination mydriatic ophthalmic solutions to accommodate the variety of medical procedures and patient parameters. The three active ingredients used in this study are all generic drugs available as manufactured ophthalmic solutions or pure powders (USP grade) which are convenient source materials for compounding combination solutions.
Since ophthalmic solutions must be sterile, it is important to consider the quality of the source materials and follow the pertinent requirements in USP general chapter <797>. 8 To minimize potential microbial contamination, it is preferred to use manufactured ophthalmic solutions (sterile) as the source materials. However, the use of non-sterile pure powders may be necessary to achieve desired drug concentrations. In that case, the final solution requires sterilization and is considered high-risk for inadvertent microbial contamination according to USP <797>. 8 In this study, the stability samples were prepared from phenylephrine powder and manufactured ophthalmic solutions of tropicamide and cyclopentolate. The final solutions were sterilized by cold sterile filtration.
The freshly prepared pediatric and adult ophthalmic solutions appeared clear, colorless, and free of particulates. The pH and the initial drug concentration values are reported in Table 1 and Table 2 , respectively. Throughout the 60-day storage at refrigeration, no significant changes of visual appearance were observed in any of the stability samples. The pH of all samples remained within the pre-defined acceptable range of 4.2 to 5.8 ( Table 1 ). The stability-indicating HPLC analysis also confirmed that all pediatric samples retained 99-102% of the initial drug concentrations and all adult samples retained 97-100% (Table 2) . No significant degradation peaks were observed in the chromatograms for either the pediatric or the adult formulations.
Overall, both pediatric and adult ophthalmic solutions exhibited satisfactory physical and chemical stability at refrigeration for up to 60 days.
There are two major limitations to the study. First, sterility testing was not performed for any of the stability samples, because the study aims were limited to chemical and physical stability. However, it is essential to follow USP <797> requirements and perform the necessary testing for the actual preparations for patient use. Secondly, this study utilized two manufactured ophthalmic solutions which contained additional excipients, such as boric acid, edetate disodium, and benzalkonium chloride. It was not studied whether the stability results would remain the same without these excipients. Therefore, it is advised that the stability results from this study may be applicable to only formulations prepared using similar source materials.
Conclusion
Two mydriatic ophthalmic solutions were prepared extemporaneously for pediatric and adult patients respectively. The pediatric solution contained phenylephrine 2.5%, tropicamide 0.5%, and cyclopentolate 0.5%. The adult solution contained phenylephrine 2.5% and tropicamide 1.0%. Both solutions were physically and chemically stable for up to 60 days at refrigeration (2-8° C). These results can be used to aid in the selection of an appropriate beyonduse date. Additionally, proper sterile compounding practice and microbiological testing as per USP <797> must be strictly followed when preparing these ophthalmic solutions for actual patient use. 
Footnotes
